Satvat Ali J. 4

What Happened Satvat Ali J., a director of Coherus Oncology (CHRS), received equity awards on June 5, 2026: 30,000 restricted stock units (RSUs) and 60,000 derivative awards (option-like). Both grants show $0.00 paid on the Form 4 (company compensation awards rather than open-market purchases). Together the awards total 90,000 equity instruments subject to future vesting.

Key Details

• Transaction date: June 5, 2026; Form 4 filed June 9, 2026 (filed on time).
• Consideration: $0.00 reported for each grant (award/compensation, not a cash purchase).
• Award breakdown: 30,000 RSUs (F1) and 60,000 derivative awards (F2).
• Vesting: F1 — RSUs convert 1:1 to common shares and vest 100% on June 3, 2027, subject to continued service. F2 — underlying shares become exercisable/vest 100% on June 3, 2027, subject to continued service.
• Shares owned after the transactions: not specified in the provided filing details.
• Filing timeliness: Filed June 9, 2026 for a June 5 transaction — within the standard Form 4 reporting window.

Context These were compensation grants (awards), a routine form of insider compensation and not an open-market purchase or sale. The 30,000 RSUs will convert to shares at vesting; the 60,000 derivative awards give rights to acquire shares in the future if the recipient remains employed/serving through the vesting date. Such awards indicate expected future ownership potential but do not reflect an immediate purchase or sale.